|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2009-8-11
|
|
pubmed:abstractText |
17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat-shock protein 90 (Hsp90) inhibitor, has been intensively investigated for cancer therapy and is undergoing clinical trials. Human epidermal growth factor receptor 2 (HER-2) is one of the client proteins of Hsp90 and its expression is decreased upon 17-DMAG treatment. In this study, we aimed to noninvasively monitor the HER-2 response to 17-DMAG treatment in xenografted mice.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/17-(dimethylaminoethylamino)-17-deme...,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Benzoquinones,
http://linkedlifedata.com/resource/pubmed/chemical/Copper Radioisotopes,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorodeoxyglucose F18,
http://linkedlifedata.com/resource/pubmed/chemical/HSP90 Heat-Shock Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Lactams, Macrocyclic,
http://linkedlifedata.com/resource/pubmed/chemical/Organometallic Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1619-7089
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
36
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1510-9
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19440708-Animals,
pubmed-meshheading:19440708-Antibodies, Monoclonal,
pubmed-meshheading:19440708-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:19440708-Benzoquinones,
pubmed-meshheading:19440708-Cell Line, Tumor,
pubmed-meshheading:19440708-Copper Radioisotopes,
pubmed-meshheading:19440708-Female,
pubmed-meshheading:19440708-Fluorodeoxyglucose F18,
pubmed-meshheading:19440708-HSP90 Heat-Shock Proteins,
pubmed-meshheading:19440708-Humans,
pubmed-meshheading:19440708-Lactams, Macrocyclic,
pubmed-meshheading:19440708-Mice,
pubmed-meshheading:19440708-Mice, Nude,
pubmed-meshheading:19440708-Neoplasm Transplantation,
pubmed-meshheading:19440708-Organometallic Compounds,
pubmed-meshheading:19440708-Ovarian Neoplasms,
pubmed-meshheading:19440708-Positron-Emission Tomography,
pubmed-meshheading:19440708-Receptor, erbB-2,
pubmed-meshheading:19440708-Tissue Distribution
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with (64)Cu-DOTA-trastuzumab.
|
|
pubmed:affiliation |
The Molecular Imaging Program at Stanford (MIPS), Department of Radiology and Bio-X Program, Stanford University School of Medicine, 1201 Welch Rd, P095, Stanford, CA 94305-5484, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, Non-P.H.S.,
Research Support, N.I.H., Extramural
|
